Wooten Marc
VA Northern Indiana Healthcare System, Indiana University School of Medicine, Fort Wayne, Indiana 46805, USA.
South Med J. 2008 Jan;101(1):59-62. doi: 10.1097/SMJ.0b013e31815838ce.
Malignancy is associated with systemic sclerosis in between 3.6 and 10.7% of patients diagnosed with systemic sclerosis. The diagnosis of systemic sclerosis may occur before, concurrent with, or after the diagnosis of malignancy. All published reports of malignancy with systemic sclerosis are reviewed. Lung cancer is the most frequent type of cancer seen in patients with systemic sclerosis, followed by breast cancer. Risk factors for the development of malignancy in patients with systemic sclerosis are female gender, increased age, and diffuse systemic sclerosis. Autoantibodies such as anticentromere and antitopoisomerase I are inconsistent in their risk for developing malignancy. Vigilance is recommended in this group of patients based on their increased risk of developing cancer.
在诊断为系统性硬化症的患者中，3.6%至10.7%的患者存在恶性肿瘤与系统性硬化症相关的情况。系统性硬化症的诊断可能在恶性肿瘤诊断之前、同时或之后出现。对所有已发表的系统性硬化症合并恶性肿瘤的报告进行了综述。肺癌是系统性硬化症患者中最常见的癌症类型，其次是乳腺癌。系统性硬化症患者发生恶性肿瘤的危险因素包括女性性别、年龄增长和弥漫性系统性硬化症。抗着丝点抗体和抗拓扑异构酶I等自身抗体在发生恶性肿瘤的风险方面并不一致。鉴于这组患者患癌风险增加，建议保持警惕。
